School of Medicine, University of Auckland, Auckland, New Zealand.
School of Population Health, University of Auckland, Auckland, New Zealand.
Clin Pharmacol Ther. 2020 Mar;107(3):580-587. doi: 10.1002/cpt.1644. Epub 2019 Oct 31.
Acute pancreatitis (AP) often progresses to recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP). We investigated the relationship between the use of insulin after AP and progression from AP to RAP or CP, as well as the effect of diabetes status on the relationship. Using nationwide pharmaceutical dispensing data and hospital discharge data, insulin-naïve individuals were followed from first AP admission. Multivariable time-dependent Cox regression analyses were conducted. In the overall cohort (n = 10,190), ever-use of insulin was associated with an increased risk of progression to RAP or CP (adjusted hazard ratio (HR), 1.70; 95% confidence interval (CI), 1.31-2.20). This risk remained increased in individuals with preexisting diabetes (adjusted HR, 1.45; 95% CI, 1.04-2.00), those with diabetes after AP (3.87; 1.20-12.46), and those without diabetes (2.80; 1.25-6.25). The findings suggest that individuals with AP who receive insulin are at a heightened risk of progression of pancreatitis, irrespective of diabetes status.
急性胰腺炎(AP)常进展为复发性急性胰腺炎(RAP)和慢性胰腺炎(CP)。我们研究了 AP 后使用胰岛素与从 AP 进展为 RAP 或 CP 的关系,以及糖尿病状态对这种关系的影响。使用全国性的药物配药数据和住院数据,对首次 AP 入院的胰岛素初治个体进行随访。进行多变量时依 Cox 回归分析。在总体队列(n=10190)中,曾使用胰岛素与进展为 RAP 或 CP 的风险增加相关(调整后的危险比(HR),1.70;95%置信区间(CI),1.31-2.20)。这种风险在有糖尿病病史的个体(调整后的 HR,1.45;95% CI,1.04-2.00)、AP 后发生糖尿病的个体(3.87;1.20-12.46)和无糖尿病的个体(2.80;1.25-6.25)中仍然增加。这些发现表明,接受胰岛素治疗的 AP 患者无论糖尿病状态如何,胰腺炎进展的风险都更高。